IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer

Kargi A., Yalcin A. D., ERİN N., Savas B., Polat H. H., Gorczynski R. M.

CLINICAL LABORATORY, vol.58, pp.501-505, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 58
  • Publication Date: 2012
  • Journal Name: CLINICAL LABORATORY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.501-505
  • Sivas Cumhuriyet University Affiliated: Yes

Abstract

Background: Colorectal cancer is the third most common human cancer and the third leading cause of cancer related death. BevacizumAb is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic cancers.